Allosensitization in heart transplantation: implications and management strategies

被引:43
作者
Mehra, MR [1 ]
Uber, PA [1 ]
Uber, WE [1 ]
Scott, RL [1 ]
Park, MH [1 ]
机构
[1] Alton Ochsner Med Fdn & Ochsner Clin, Dept Cardiovasc Med, Cardiomyopathy & Heart Transplant Ctr, New Orleans, LA 70121 USA
关键词
D O I
10.1097/00001573-200303000-00015
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The detection of anti-human leukocyte antigen (HILA) donor-specific antibodies has been associated with a variety of clinical syndromes that determine short-term and long-term outcomes of cardiac transplant recipients, including an increased incidence of early and more severe allograft rejection and cardiac allograft vasculopathy. Recent surveys indicate marked heterogeneity in clinical protocols for detection and management of sensitization in heart transplantation. The commonly performed complement-dependent cytotoxicity assay is insensitive compared with newer methods such as flow cytometry for antibody screening. The imperative exists to create strategies that can decrease the level of sensitization and increase the likelihood for a negative crossmatch. In this effort, several strategies have been suggested, including administration of intravenous immunoglobulin, apheresis, and combination therapies using potent immunosuppression, particularly with cyclophosphamide. The future of managing allosensitization may be in induction of a chimeric state to allow graft tolerance. (C) 2003 Lippincott Williams Wilkins.
引用
收藏
页码:153 / 158
页数:6
相关论文
共 36 条
[1]   Activation-induced T-cell death and immune dysfunction after implantation of left-ventricular assist device [J].
Ankersmit, HJ ;
Tugulea, S ;
Spanier, T ;
Weinberg, AD ;
Artrip, JH ;
Burke, EM ;
Flannery, M ;
Mancini, D ;
Rose, EA ;
Edwards, NM ;
Oz, MC ;
Itescu, S .
LANCET, 1999, 354 (9178) :550-555
[2]   Stem cell transplantation eliminates alloantibody in a highly sensitized patient [J].
Bartholomew, A ;
Sher, D ;
Sosler, S ;
Stock, W ;
Lazda, V ;
Koshy, M ;
Devine, S ;
vanBesien, K .
TRANSPLANTATION, 2001, 72 (10) :1653-1655
[3]   Panel-reactive antibody screening practices prior to heart transplantation [J].
Betkowski, AS ;
Graff, R ;
Chen, JJ ;
Hauptman, PJ .
JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2002, 21 (06) :644-650
[4]   Elimination of alloantibodies by immunoablative high dose cyclophosphamide [J].
Brodsky, RA ;
Fuller, AK ;
Ratner, LE ;
Leffell, MS ;
Jones, RJ .
TRANSPLANTATION, 2001, 71 (03) :482-484
[5]  
Cho Y W, 2001, Clin Transpl, P237
[6]   The abrogation of allosensitization following the induction of mixed allogeneic chimerism [J].
Colson, YL ;
Schuchert, MJ ;
Ildstad, ST .
JOURNAL OF IMMUNOLOGY, 2000, 165 (02) :637-644
[7]  
DEMATTOS AM, 1994, TRANSPLANTATION, V57, P626
[8]   The role of intravenous immunoglobulin therapy in autoimmune and inflammatory disorders [J].
Emmi, L ;
Chiarini, F .
NEUROLOGICAL SCIENCES, 2002, 23 (Suppl 1) :S1-S8
[9]   Sensitization and sensitivity - Defining the unsensitized patient [J].
Gebel, HM ;
Bray, RA .
TRANSPLANTATION, 2000, 69 (07) :1370-1374
[10]  
Hardy S, 2001, Clin Transpl, P271